…
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Plus Therapeutics Inc develops targeted radiotherapeutics using nanoliposome and radiopharmaceutical technologies for oncology indications with high unmet need. Its long-term growth may be supported by successful clinical trials, regulatory approvals, indication expansion and manufacturing or partner scale-up. The company appears positioned to attract investors interested in niche oncology platforms that could benefit from growing adoption of targeted radiotherapy.
The most important investment risks are clinical and regulatory execution risk, likely ongoing capital requirements and manufacturing complexity that could delay commercialization or cause dilution.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -22.39M | -12.98M | -13.32M | -20.27M | -13.40M |
| Net income | -22.39M | -12.98M | -13.32M | -20.84M | -14.33M |
| Selling general administrative | 12.13M | 9.94M | 8.54M | 10.24M | 6.85M |
| Selling and marketing expenses | - | - | 0.74M | - | - |
| Gross profit | 4.77M | 4.97M | -4.78M | 0.22M | -0.07M |
| Reconciled depreciation | 0.45M | 0.72M | 0.63M | 0.62M | 0.40M |
| Ebit | -18.78M | -9.25M | -12.92M | -19.71M | -12.49M |
| Ebitda | -18.33M | -8.40M | -12.29M | -18.95M | -12.01M |
| Depreciation and amortization | 0.45M | 0.85M | 0.63M | 0.77M | 0.48M |
| Operating income | -15.30M | -14.70M | -13.32M | -19.71M | -12.49M |
| Other operating expenses | 20.51M | 20.52M | 18.23M | 19.94M | 12.43M |
| Interest expense | 3.61M | 3.72M | 0.40M | 0.71M | 0.93M |
| Interest income | 0.12M | 0.27M | 0.40M | 0.15M | 0.02M |
| Net interest income | -3.49M | -3.45M | 0.01M | -0.56M | -0.91M |
| Income tax expense | - | - | - | 0.56M | 0.93M |
| Total revenue | 5.21M | 5.82M | 4.91M | 0.22M | 0.00M |
| Total operating expenses | 20.07M | 19.67M | 8.54M | 19.94M | 12.43M |
| Cost of revenue | 0.45M | 0.85M | 9.69M | - | 0.07M |
| Total other income expense net | -7.09M | 1.72M | 0.01M | -0.56M | -0.91M |
| Net income from continuing ops | -22.39M | -12.98M | -13.32M | -20.27M | -13.40M |
| Net income applicable to common shares | - | - | - | -20.27M | -13.40M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 16.32M | 6.63M | 11.39M | 23.87M | 21.98M |
| Intangible assets | 0.33M | 0.47M | 0.04M | 0.09M | 0.05M |
| Other current assets | 6.41M | 1.08M | 1.28M | 3.70M | 1.32M |
| Total liab | 12.33M | 15.58M | 12.74M | 17.42M | 11.14M |
| Total stockholder equity | 4.00M | -8.95M | -1.35M | 6.45M | 10.84M |
| Other current liab | 8.23M | 2.74M | 1.87M | 1.77M | 0.12M |
| Common stock | 0.14M | 0.01M | 0.01M | 0.03M | 0.02M |
| Capital stock | 0.14M | 0.01M | 0.01M | 0.03M | 0.02M |
| Retained earnings | -515.87M | -493.48M | -480.50M | -467.19M | -446.91M |
| Other liab | - | - | - | 1.64M | 0.00M |
| Good will | 0.37M | 0.37M | 0.37M | 0.37M | 0.37M |
| Other assets | - | - | - | 0.01M | 0.02M |
| Cash | 8.76M | 0.08M | 8.55M | 18.12M | 18.40M |
| Total current liabilities | 12.31M | 15.55M | 10.73M | 11.85M | 5.87M |
| Current deferred revenue | - | - | - | - | 1.42M |
| Net debt | -7.94M | 3.29M | -4.37M | -12.47M | -11.41M |
| Short term debt | 0.81M | 3.34M | 4.10M | 1.72M | 1.72M |
| Short long term debt | 0.75M | 3.29M | 3.98M | 1.61M | 1.61M |
| Short long term debt total | 0.82M | 3.37M | 4.18M | 5.64M | 6.99M |
| Other stockholder equity | 519.72M | 484.52M | 479.15M | 473.60M | 457.73M |
| Property plant equipment | - | - | - | 1.57M | 1.82M |
| Total current assets | 15.17M | 5.26M | 9.83M | 21.82M | 19.72M |
| Net tangible assets | - | - | - | 5.98M | 10.41M |
| Short term investments | 4.36M | 3.53M | - | - | - |
| Net receivables | - | 0.57M | - | - | 0.01M |
| Long term debt | - | - | - | 3.79M | 5.00M |
| Inventory | - | - | - | - | -0.01M |
| Accounts payable | 3.28M | 9.47M | 4.76M | 8.36M | 2.61M |
| Accumulated other comprehensive income | - | - | 0.00M | - | - |
| Non currrent assets other | 0.12M | 0.01M | 0.03M | 0.01M | 0.02M |
| Non current assets total | 1.16M | 1.37M | 1.55M | 2.05M | 2.26M |
| Capital lease obligations | 0.07M | 0.07M | 0.20M | 0.25M | 0.38M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -0.82M | -4.11M | -0.16M | -0.76M | -0.08M |
| Change to liabilities | - | - | - | 6.45M | 1.73M |
| Total cashflows from investing activities | -0.85M | -4.11M | -0.16M | -0.76M | -0.08M |
| Net borrowings | -2.51M | -0.70M | -1.61M | -1.61M | -0.28M |
| Total cash from financing activities | 30.31M | 6.19M | 3.44M | 13.45M | 20.42M |
| Change to operating activities | - | - | - | -0.85M | -0.50M |
| Net income | -22.39M | -12.98M | -13.32M | -20.27M | -13.40M |
| Change in cash | 8.68M | -8.48M | -9.57M | -0.28M | 10.05M |
| Begin period cash flow | 0.08M | 8.55M | 18.12M | 18.40M | 8.35M |
| End period cash flow | 8.76M | 0.08M | 8.55M | 18.12M | 18.40M |
| Total cash from operating activities | -20.77M | -10.55M | -12.85M | -12.97M | -10.28M |
| Issuance of capital stock | 38.54M | 7.26M | 5.53M | 15.06M | 18.68M |
| Depreciation | 0.45M | 0.72M | 0.63M | 0.62M | 0.40M |
| Other cashflows from investing activities | 0.03M | -0.55M | - | - | - |
| Dividends paid | - | - | 0.35M | - | - |
| Change to account receivables | 0.25M | -0.57M | - | - | 0.00M |
| Sale purchase of stock | 0.00M | -0.37M | -0.13M | - | - |
| Other cashflows from financing activities | 19.37M | -0.70M | -0.35M | -0.76M | 2.02M |
| Change to netincome | - | - | - | 0.60M | 0.94M |
| Capital expenditures | 0.07M | 0.15M | 0.16M | 0.51M | 0.14M |
| Change in working capital | -6.04M | 3.22M | -1.12M | 5.60M | 1.24M |
| Stock based compensation | 1.54M | 0.55M | 0.57M | 0.61M | 0.61M |
| Other non cash items | 5.67M | -2.07M | 0.38M | 0.48M | 0.82M |
| Free cash flow | -20.84M | -10.70M | -13.01M | -13.48M | -10.42M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
6420 LEVIT GREEN BOULEVARD, Houston, TX, United States, 77021
737 255 7194
28
| Name | Title | Year Born |
|---|---|---|
| Dr. Marc H. Hedrick M.D. | Pres, CEO & Director | 1963 |
| Mr. Andrew J. Sims | VP & CFO | 1974 |
| Dr. Norman D. LaFrance FACNP, FACP, M.D. | Chief Medical Officer & Sr. VP | 1948 |
| Ms. Desiree Smith | Corp. Controller, Principal Financial & Accounting Officer | 1964 |
| Dr. John K. Fraser | Chief Scientist | 1961 |
| Mr. Russ Havranek M.B.A., M.S. | VP of Corp. Strategy, New Product Planning & Investor Relations | NA |
| Mr. Gary S. Titus CPA | Advisor | 1960 |
| Dr. Marc H. Hedrick M.B.A., M.D. | President, CEO & Director | 1963 |
| Mr. Andrew J. Sims CPA | VP of Finance & CFO | 1973 |
| Dr. Norman D. LaFrance FACNP, FACP, M.D. | Chief Medical Officer & Senior VP | 1948 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.